First Manhattan
TCRT icon

First Manhattan’s Alaunos Therapeutics TCRT Stock Holding History

First Manhattan’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-133
Closed -$215K – 1493
2015
Q1 		$215K Buy
+133
New +$197K ﹤0.01% 677

Other funds holding TCRT

UOTTAIMCU
University of Texas/Texas AM Investment Management Co (UTIMCO) Austin, Texas $687M AUM 21.33% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MVP
Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
TP
Third Point New York $2.08B AUM 27.04% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

First Manhattan's TCRT Position: Q2 2015 in Review

First Manhattan sold out of Alaunos Therapeutics (TCRT) in Q2 2015, closing a stake of 133 shares — an estimated $215K sold.

First Manhattan first reported a position in TCRT in Q1 2015 and held it in 1 quarter. The position peaked at $215K in Q1 2015. 156 funds tracked by Wall St. Rank hold TCRT as of Q2 2015.

  • First Manhattan reported no remaining Alaunos Therapeutics position as of Q2 2015 after selling out during the quarter.
  • First Manhattan sold 133 Alaunos Therapeutics shares in Q2 2015, an estimated $215K.
  • First Manhattan first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 1 quarter.
  • First Manhattan's Alaunos Therapeutics position peaked at $215K in Q1 2015.
  • 156 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2015.

Based on First Manhattan's 13F filing for Q2 2015, filed 17 Jul 2015.